Nirsevimab (Beyfortus) may reduce severe respiratory syncytial virus infections among infants
1. In this large case-control study across 7 tertiary pediatric hospitals, receiving Nirsevimab (Beyfortus) among symptomatic infants with respiratory syncytial ...


![RSV positivity associated with reduced serious bacterial infection risk [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/09/800px-Respiratory_syncytial_virus_01-350x250.jpg)




